Clinical data | |
---|---|
Trade names | Vivactyl, others |
Other names | Amimethyline; Protriptyline hydrochloride; MK-240 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a604025 |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 77–93%[2] |
Protein binding | 92%[2] |
Metabolism | Hepatic |
Elimination half-life | 54–92 hours |
Excretion | Urine: 50%[2] Feces: minor[2] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.474 |
Chemical and physical data | |
Formula | C19H21N |
Molar mass | 263.384 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Protriptyline, sold under the brand name Vivactil among others, is a tricyclic antidepressant (TCA), specifically a secondary amine, indicated for the treatment of depression and attention-deficit hyperactivity disorder (ADHD). Uniquely among most of the TCAs, protriptyline tends to be energizing instead of sedating, and is sometimes used for narcolepsy to achieve a wakefulness-promoting effect.
TCAs including protriptyline are also used to reduce the incidence of recurring headaches such as migraine, and for other types of chronic pain.